Cutting-Edge Research
At Kaizen Brain Center, we continually seek to conduct cutting-edge clinical research to find new cures for various brain conditions. As a data-driven medical practice, we analyze patient needs and advance our care to meet individual health goals. Our research is governed by a rigorous scientific evaluation of the risks and benefits, prioritizing patient well-being.
Our current studies explore treatments for depression, Alzheimer’s Disease, migraine, trigeminal neuralgia, traumatic brain injury, and obsessive-compulsive disorder. Please review our active studies below and speak to your provider about getting involved with research at Kaizen Brain Center.
Active Research Studies
Alzheimer’s Disease | Study LAKC is a multicenter, randomized, double-blind, placebo-controlled, Phase 3 Study of Remternetug in participants who had early symptomatic AD. | Collin Liu, MD | Eli Lilly | J1G-MC-LAKC
Trigeminal Neuralgia | Phase 2: A Double-Blind, Placebo-Controlled, Crossover Trial of BHV-3000 (Rimegepant) for Treatment Refractory Trigeminal Neuralgia | Hossein Ansari, MD, FAAN, FAHS | Biohaven | BHV3000-202
Trigeminal Neuralgia | A Phase II/III, multicenter, 8-week run-in phase followed by a 12-week, prospective, parallel-group, double-blind, randomized withdrawal, placebo-controlled study, with a 52 week open label extension, to evaluate the efficacy and safety of daily 1.5 to 3.5 mg basimglurant in patients with pain associated with trigeminal neuralgia with suboptimal response to their current anti-pain therapy. | Hossein Ansari, MD, FAAN, FAHS | Noema | NOE-TGN-201
Obsessive Compulsive Disorder | A Randomized, Double-Blind, Placebo-Controlled Trial of Adjunctive Troriluzole in Obsessive Compulsive Disorder | Mohammed Ahmed, MD | Biohaven | BHV4157-303 Migraine | An Open-Label, Multiple-Dose Evaluation of the Efficacy and Safety of AXS-07 for the Acute Treatment of Migraine in Adults with a Prior Inadequate Response to an Oral CGRP Inhibitor | Hossein Ansari, MD, FAAN, FAHS | Axsome | AXS-07-304
Treatment-resistant Depression | A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy System as Adjunctive Therapy Versus a No-Stimulation Control in Subjects With Treatment-Resistant Depression | Mohammed Ahmed, MD | LivaNova | LND-300
Get Involved with Research at Kaizen Brain Center
If you are interested in participating in one of our research studies or would like more information, please speak with your Kaizen Brain Center provider. Your provider can help determine if you are eligible for a study and guide you through the process of participation.
We believe that research is essential for advancing our understanding of complex neurological disorders and improving patient outcomes. Join us in our mission to transform lives through innovative, evidence-based treatments.
Call our Research Team today at 858-294-0161 to learn more about how you can get involved. Let’s work together to improve lives and transform the future of medical care.